Silvio Danese

Summary

Publications

  1. ncbi request reprint Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation
    Silvio Danese
    Instituto di Ricerca e Cura a Carattere Scientifico Istituto Clinico Humanitas, Milan, Italy
    J Immunol 178:6017-22. 2007
  2. ncbi request reprint Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow
    Silvio Danese
    Division of Gastroenterology, Laboratory of Inflammation and Immunology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Curr Opin Gastroenterol 23:384-9. 2007
  3. pmc Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease
    Franco Scaldaferri
    Division of Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas, Rozzano, Italy
    J Clin Invest 117:1951-60. 2007
  4. ncbi request reprint Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside
    Manol Jovani
    IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas ICH 20089, Rozzano, Milan, Italy
    Curr Drug Targets 14:1444-52. 2013
  5. ncbi request reprint Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target
    Mariangela Allocca
    IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas ICH 20089, Rozzano, Milan, Italy
    Curr Drug Targets 14:1508-21. 2013
  6. ncbi request reprint Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells
    Manol Jovani
    IBD Center, Department of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy
    Curr Drug Targets 14:1433-43. 2013
  7. doi request reprint IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs
    Silvio Danese
    IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Centre, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Nat Rev Gastroenterol Hepatol 10:511-2. 2013
  8. doi request reprint ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
    Silvio Danese
    IBD Center, Humanitas Clinical and Research Centre, Milan, Italy
    J Crohns Colitis 7:586-9. 2013
  9. doi request reprint Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future
    S Danese
    IBD Center, Humanitas Clinical and Research Centre, Milan, Italy
    Aliment Pharmacol Ther 37:855-66. 2013
  10. doi request reprint Adalimumab in ulcerative colitis: ready for prime time
    Silvio Danese
    Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Dig Liver Dis 45:8-13. 2013

Detail Information

Publications127 found, 100 shown here

  1. ncbi request reprint Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation
    Silvio Danese
    Instituto di Ricerca e Cura a Carattere Scientifico Istituto Clinico Humanitas, Milan, Italy
    J Immunol 178:6017-22. 2007
    ....
  2. ncbi request reprint Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow
    Silvio Danese
    Division of Gastroenterology, Laboratory of Inflammation and Immunology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Curr Opin Gastroenterol 23:384-9. 2007
    ..Inflammatory bowel disease pathogenesis involves the interplay of multiple biological factors, among which nonimmune cells, including the endothelium, represent a crucial component of disease pathogenesis...
  3. pmc Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease
    Franco Scaldaferri
    Division of Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas, Rozzano, Italy
    J Clin Invest 117:1951-60. 2007
    ..Restoring the PC pathway may represent a new therapeutic approach to suppress intestinal inflammation in IBD...
  4. ncbi request reprint Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside
    Manol Jovani
    IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas ICH 20089, Rozzano, Milan, Italy
    Curr Drug Targets 14:1444-52. 2013
    ..Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases. ..
  5. ncbi request reprint Anti-IL-6 treatment for inflammatory bowel diseases: next cytokine, next target
    Mariangela Allocca
    IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas ICH 20089, Rozzano, Milan, Italy
    Curr Drug Targets 14:1508-21. 2013
    ..In this review, we discuss the role of IL-6 in chronic inflammation, with particular emphasis on its role in CD and UC, and we explore the potential to develop anti-IL-6 agents for IBD treatment. ..
  6. ncbi request reprint Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells
    Manol Jovani
    IBD Center, Department of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy
    Curr Drug Targets 14:1433-43. 2013
    ..These data allow to confidently prospect that vedolizumab will be an important therapeutic option in the future of IBD treatment. ..
  7. doi request reprint IBD: Golimumab in ulcerative colitis: a 'ménage à trois' of drugs
    Silvio Danese
    IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Centre, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Nat Rev Gastroenterol Hepatol 10:511-2. 2013
    ..The addition of this drug makes a ménage à trois of available drugs--comprising infliximab, adalimumab and golimumab--for the treatment of ulcerative colitis...
  8. doi request reprint ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)
    Silvio Danese
    IBD Center, Humanitas Clinical and Research Centre, Milan, Italy
    J Crohns Colitis 7:586-9. 2013
    ..Switching from an established biologic to a biosimilar to save costs is likely to be as inappropriate and inefecctive as switching between current biologics that act on the same target, except when there is loss of response...
  9. doi request reprint Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future
    S Danese
    IBD Center, Humanitas Clinical and Research Centre, Milan, Italy
    Aliment Pharmacol Ther 37:855-66. 2013
    ..Anti-tumour necrosis factor (TNF) agents are recent additions to the UC-treatment algorithm...
  10. doi request reprint Adalimumab in ulcerative colitis: ready for prime time
    Silvio Danese
    Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Dig Liver Dis 45:8-13. 2013
    ..Here, the current evidence regarding use of adalimumab in the treatment of ulcerative colitis is reviewed, with results indicating that adalimumab has compelling efficacy in the treatment of moderate-to-severe ulcerative colitis...
  11. ncbi request reprint Bowel damage assessment in Crohn's disease by magnetic resonance imaging
    Gionata Fiorino
    IBD Center, Gastroenterology, IRCCS Humanitas, Via Manzoni 56, Rozzano, Milan, Italy
    Curr Drug Targets 13:1300-7. 2012
    ....
  12. doi request reprint New therapies for inflammatory bowel disease: from the bench to the bedside
    Silvio Danese
    IBD Center, Division of Gastroenterology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Gut 61:918-32. 2012
    ..This study systematically reviews the mechanisms of action, efficacy and safety of new and emerging therapies that are currently in clinical trials and discusses future directions in the treatment of IBD...
  13. pmc Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies
    Giuseppina Bonanno
    Department of Hematology, Catholic University Med, School, Rome, Italy
    J Transl Med 8:114. 2010
    ....
  14. ncbi request reprint Angiogenesis as a novel component of inflammatory bowel disease pathogenesis
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy
    Gastroenterology 130:2060-73. 2006
    ..We assessed mucosal vascularization, expression of endothelial alphaVbeta3 integrin, angiogenic factors, and their bioactivity in Crohn's disease (CD) and ulcerative colitis (UC) mucosa...
  15. ncbi request reprint Biological therapies for inflammatory bowel disease: research drives clinics
    Silvio Danese
    IBD, Division of Gastroenterology, Istituto Clinico Humanitas IRCCS in Gastroenterology, Viale Manzoni 56, 20089, Rozzano, Milan, Italy
    Mini Rev Med Chem 6:771-84. 2006
    ..Aim of this article is to review the biological compounds and their efficacy in IBD...
  16. pmc The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications
    Silvio Danese
    IBD Unit, Division of Gastroenterology, Istituto Clinico Humanitas IRCCS, Rozzano, Italy
    Blood 115:1121-30. 2010
    ....
  17. doi request reprint VEGF in inflammatory bowel disease: a master regulator of mucosal immune-driven angiogenesis
    S Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy
    Dig Liver Dis 40:680-3. 2008
  18. doi request reprint New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    S Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy
    Gastroenterol Clin Biol 33:S217-27. 2009
    ..This paper systematically reviews the mechanismof-action, efficacy, short-term and, where available, long-term safety of biological agents that target molecules other than tumor necrosis factor alpha, in IBD...
  19. ncbi request reprint TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease
    Silvio Danese
    Department of Internal Medicine, Catholic University, Rome, Italy
    J Immunol 176:2617-24. 2006
    ..Thus, in addition to neutralizing TNF-alpha and inducing T cell death, the therapeutic effects of infliximab in CD appear to be also mediated by inhibition of vascular inflammation in the gut...
  20. ncbi request reprint Extraintestinal manifestations in inflammatory bowel disease
    Silvio Danese
    Department of Internal Medicine, Catholic University School of Medicine, L go Vito 1, Rome 00168, Italy
    World J Gastroenterol 11:7227-36. 2005
    ....
  21. ncbi request reprint Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer
    S Danese
    Inflammatory Bowel Disease Unit, Division of Gastroenterology, Milan, Italy
    Oncogene 29:3313-23. 2010
    ..Dissection of molecular pathways involved in colitis-associated cancer may offer opportunities for innovative therapeutic strategies...
  22. pmc Angiogenesis blockade as a new therapeutic approach to experimental colitis
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Milan 20089, Italy
    Gut 56:855-62. 2007
    ..Neoangiogenesis is a critical component of chronic inflammatory disorders. Inhibition of angiogenesis is an effective treatment in animal models of inflammation, but has not been tested in experimental colitis...
  23. pmc Critical role of the CD40 CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease
    S Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Gut 56:1248-56. 2007
    ..The present study evaluated the role of the CD40-CD40L interaction in the promotion of immune-mediated angiogenesis in IBD...
  24. doi request reprint Cytapheresis in inflammatory bowel diseases: current evidence and perspectives
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, University of Milan, Rozzano Milan, Italy
    Digestion 77:96-107. 2008
    ....
  25. doi request reprint Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker
    S Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy
    Dig Liver Dis 40:S225-8. 2008
    ..Infliximab, a monoclonal antibody against TNF-alpha has been proved highly effective in the clinical management of both forms of IBD. Aim of this paper is to review the mechanisms of action of infliximab in IBD...
  26. doi request reprint PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system
    Silvio Danese
    Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Eur J Gastroenterol Hepatol 20:826-8. 2008
    ..Recent studies have shown an imbalance of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor, suggesting that these molecules might contribute to thromboembolic events in both forms of IBD...
  27. ncbi request reprint Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy
    Curr Med Chem 14:1489-97. 2007
    ..The aim of this paper is to critically review the rationale and state-of-the art for the use TNF- alpha inhibitors in the treatment of CD...
  28. doi request reprint Nonimmune cells in inflammatory bowel disease: from victim to villain
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan 20089, Italy
    Trends Immunol 29:555-64. 2008
    ..I describe the current knowledge of the roles played by nonimmune cells in the pathogenesis of IBD, as they emerge as crucial alternative targets for therapeutic intervention...
  29. ncbi request reprint Biological agents for ulcerative colitis: hypes and hopes
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy
    Med Res Rev 28:201-18. 2008
    ..However, the recent introduction of biological therapies has led to promising changes in the management of UC patients. Aim of this paper is to review the recent advances and future perspectives for the use of biological agents in UC...
  30. ncbi request reprint Oral beclomethasone: a review of its use in inflammatory bowel disease
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas IRCCS in Gastroenterology, Viale Manzoni, Rozzano, Milan, Italy
    Mini Rev Med Chem 8:1459-63. 2008
    ..Aim of this paper is to review mechanisms of action, safety and efficacy of beclomethasone dipropionate, a steroid with enhanced topical intestinal activity and low systemic activity, in the treatment of inflammatory bowel disease...
  31. pmc Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study
    Silvio Danese
    Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Viale Manzoni, Rozzano, Milan 20089, Italy
    World J Gastroenterol 16:2396-400. 2010
    ..To investigate whether narrow band imaging (NBI) is a useful tool for the in vivo detection of angiogenesis in inflammatory bowel disease (IBD) patients...
  32. pmc Chemokines in inflammatory bowel disease
    S Danese
    Department of Internal Medicine, Gemelli Hospital, Catholic University, Rome I 00168, Italy
    J Clin Pathol 58:1025-7. 2005
  33. doi request reprint Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease
    Silvio Danese
    IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Am J Physiol Gastrointest Liver Physiol 300:G716-22. 2011
    ..The aim of this review is to summarize the current role played by each cell type in IBD pathogenesis...
  34. doi request reprint Role of the vascular and lymphatic endothelium in the pathogenesis of inflammatory bowel disease: 'brothers in arms'
    Silvio Danese
    Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Gut 60:998-1008. 2011
    ....
  35. ncbi request reprint Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease
    Silvio Danese
    Department of Internal Medicine, Institute of General Pathology, Catholic University, Rome, Italy
    Am J Gastroenterol 100:886-95. 2005
    ..Our aims were to study the levels of plasma and mucosal homocysteine in IBD patients and to assess whether homocysteine can trigger an inflammatory reaction on human intestinal microvascular endothelial cells (HIMECs)...
  36. ncbi request reprint Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease
    Silvio Danese
    Department of Internal Medicine, Catholic University of Rome, Rome, Italy
    Crit Rev Immunol 25:103-21. 2005
    ..The clinical profit to be gained from blocking this molecular pair will be determined by results in humans with conditions in which the platelet CD40/CD40 ligand pathway is crucially involved in disease pathogenesis...
  37. doi request reprint Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience
    S Danese
    Division of Gastroenterology, Instituto Clinico Humanitas, IRCCS in Gastroenterology, Via Manzoni 56, Rozzano, Milan, Italy
    Aliment Pharmacol Ther 33:857-69. 2011
    ..Over 10 years of clinical data and experience have demonstrated these therapies to be highly effective in Crohn's disease...
  38. doi request reprint Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Italy
    Pathobiology 75:22-4. 2008
    ..In addition, recombinant thrombospondin-1 may inhibit pathological angiogenesis and may offer a new therapeutic approach to intestinal inflammation...
  39. ncbi request reprint Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation
    S Danese
    Department of Internal Medicine, Catholic University School of Medicine, L go Vito 1, 00168 Rome, Italy
    Dig Liver Dis 37:811-8. 2005
    ..This paper reviews the major molecules that mediate leukocyte-endothelial interactions, and summarises the results of the most recent clinical trials targeting adhesion molecules in inflammatory bowel disease...
  40. doi request reprint IBD: of mice and men-shedding new light on IL-13 activity in IBD
    Silvio Danese
    IBD Center, IRCCS Humanitas, Via Manzoni 56, Rozzano, Milan 20089, Italy
    Nat Rev Gastroenterol Hepatol 8:128-9. 2011
    ..the decoyreceptor Il‑13rα2 inhibits this protective effect, suggesting blockade of Il‑13rα2 as a potential therapy for patients with IBD...
  41. doi request reprint VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis
    Franco Scaldaferri
    Division of Gastroenterology, Istituto Clinico Humanitas, University of Milan, Milan Department of Internal Medicine, Catholic University, Rome, Italy
    Gastroenterology 136:585-95.e5. 2009
    ..Vascular endothelial growth factor A (VEGF-A) mediates angiogenesis and might also have a role in inflammation and immunity. We examined whether VEGF-A signaling has a role in inflammatory bowel disease (IBD)...
  42. doi request reprint Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease
    Sergio Rutella
    Department of Hematology, Catholic University Medical School, Rome, Italy
    Am J Gastroenterol 106:762-70. 2011
    ....
  43. doi request reprint The role of MAPK in governing lymphocyte adhesion to and migration across the microvasculature in inflammatory bowel disease
    Franco Scaldaferri
    Istituto Clinico Humanitas IRCCS in Gastroenterology, University of Milan, Rozzano, Milan
    Eur J Immunol 39:290-300. 2009
    ..05) HIMEC monolayers. These findings suggest a critical role for MAPK in governing lymphocyte influx into the gut in IBD patients, and their blockade may offer a molecular target for blockade of leukocyte recruitment to the intestine...
  44. doi request reprint The lymphatic system controls intestinal inflammation and inflammation-associated Colon Cancer through the chemokine decoy receptor D6
    Stefania Vetrano
    Division of Gastroenterology, Istituto Clinico Humanitas IRCCS, Milan, Italy
    Gut 59:197-206. 2010
    ....
  45. doi request reprint Enhanced platelet adhesion induces angiogenesis in intestinal inflammation and inflammatory bowel disease microvasculature
    Sergio Rutella
    Department of Hematology, Catholic University Medical School, Rome, Italy
    J Cell Mol Med 15:625-34. 2011
    ..These findings suggest that inflamed HIMEC may recruit PLT which, upon release of pro-angiogenic factors, actively contribute to inflammation-induced angiogenesis...
  46. ncbi request reprint New insights into inflammatory bowel disease pathophysiology: paving the way for novel therapeutic targets
    Tommaso Stefanelli
    Division of Gastroenterology, Istituto Clinico Humanitas, Milan, Italy
    Curr Drug Targets 9:413-8. 2008
    ..Aim of this review is to summarize the recent advances in IBD pathophysiology and the new therapeutic targets and drugs that are changing the IBD clinical management...
  47. doi request reprint Unique role of junctional adhesion molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease
    Stefania Vetrano
    Division of Gastroenterology, Istituto di Ricerca e Cura a Carattere Scientifico Istituto Clinico Humanitas, University of Milan, Rozzano, Italy
    Gastroenterology 135:173-84. 2008
    ..Junctional adhesion molecule-A (JAM-A) is localized at the tight junctions and controls leukocyte migration into the tissues. However, its functional role in inflammatory bowel disease (IBD) is unexplored...
  48. pmc FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents
    Luisa Guidi
    Department of Internal Medicine, Inflammatory Bowel Disease Unit, Complesso Integrato Columbus, Catholic University, Largo Gemelli 8, 00168 Rome, Italy
    Biomed Res Int 2013:286368. 2013
    ..Our data suggest the possibility that in IBD patients the treatment with anti-TNFα may affect Treg percentages and that Treg modifications may correlate with clinical response, but differently in early versus late disease...
  49. pmc Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation
    Stefania Vetrano
    IBD Unit, Division of Gastroenterology, Istituto Clinico Humanitas IRCCS, Rozzano 20089 Milan, Italy
    Proc Natl Acad Sci U S A 108:19830-5. 2011
    ..Taken together, these findings demonstrate that the PC pathway is a unique system involved in controlling intestinal homeostasis and inflammation by regulating epithelial barrier function...
  50. pmc Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades
    Livija Deban
    Division of Gastroenterology, Istituto Clinico Humanitas IRCCS in Gastroenterology, Viale Manzoni, Rozzano, Milan, Italy
    Am J Pathol 172:1457-66. 2008
    ..In particular, we assess the multiple roles of the microvascular endothelium in innate immunity, leukocyte recruitment, coagulation and perfusion, and immune-driven angiogenesis in IBD...
  51. ncbi request reprint Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications
    Silvio Danese
    Catholic University of Rome, Rome, Italy
    Am J Gastroenterol 99:938-45. 2004
    ....
  52. ncbi request reprint Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner?
    Gionata Fiorino
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy
    Curr Drug Targets 11:249-60. 2010
    ....
  53. doi request reprint Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases
    Simone Saibeni
    Unit of Internal Medicine and Hepatology, Azienda Ospedaliera Fatebenefratelli and Oftalmico, Milan, Italy
    Int J Colorectal Dis 28:1281-6. 2013
    ..The aim of the study is to evaluate the prevalence of aPT antibodies in IBD patients, with and without thrombosis...
  54. ncbi request reprint Preoperative magnetic resonance enterography in predicting findings and optimizing surgical approach in Crohn's disease
    Antonino Spinelli
    Department of Surgery IBD Surgery Unit, Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano MI, 20089, Italy
    J Gastrointest Surg 18:83-90; discussion 90-1. 2014
    ..Intraoperative detection of new lesions may lead to change in planned surgery. This study aimed to determine whether magnetic resonance enterography can optimize surgical planning and guide decision making in Crohn's disease...
  55. doi request reprint Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response
    Carmen Correale
    Division of Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
    Gastroenterology 144:346-356.e3. 2013
    ..We investigated the expression of TREM-2 in the intestinal lamina propria and its role in the development of colonic inflammation...
  56. doi request reprint Short-term outcomes of laparoscopy combined with enhanced recovery pathway after ileocecal resection for Crohn's disease: a case-matched analysis
    Antonino Spinelli
    Department and Chair of General Surgery, Istituto Clinico Humanitas IRCCS, University of Milan, Via Alessandro Manzoni 56, 20089, Rozzano, Milan, Italy
    J Gastrointest Surg 17:126-32; discussion p.132. 2013
    ..However, no previous reports have focused on patients with Crohn's disease (CD) treated by laparoscopy and ERP...
  57. ncbi request reprint Imaging modalities for perianal Crohn's disease
    Antonino Spinelli
    Department of General Surgery, U O Chirurgia Generale III, Istituto Clinico Humanitas IRCCS, Rozzano Milano, Italy
    Curr Drug Targets 13:1287-93. 2012
    ..In this paper we review available data on each imaging modality, comparing performance and focusing on specific pros and cons, in order to assist clinicians in choosing the most appropriate treatment option for each individual patient...
  58. pmc Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?
    Franco Scaldaferri
    Division of Gastroenterology, IRCCS, Istituto Clinico Humanitas, 20089 Rozzano, Milan, Italy
    World J Gastroenterol 16:2616-25. 2010
    ....
  59. doi request reprint Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease
    Gionata Fiorino
    IBD Unit, Division of Gastroenterology and Digestive Endoscopy, IRCCS Humanitas, Rozzano, Milan, Italy
    Expert Rev Clin Immunol 6:567-72. 2010
    ..The development of a new specific molecule, vedolizumab, is currently under investigation in a large clinical trial. This novel specific anti-integrin drug seems to hold promise in the treatment of gut inflammation...
  60. doi request reprint Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go
    Tommaso Stefanelli
    Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Viale M lt anzoni, Rozzano, Milan, Italy
    Autoimmun Rev 7:364-9. 2008
    ..This review outlines the scientific basis behind this therapeutic approach, and describes the principal clinical studies that have been carried out on these new molecules in patients with IBD...
  61. ncbi request reprint Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease
    Gilles Laverny
    BioXell S p a, Milan, Italy
    Immunol Lett 131:49-58. 2010
    ..These results confirm the therapeutic efficacy of VDR agonists in experimental colitis, and suggest BXL-62 as a promising compound for IBD treatment...
  62. pmc Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment
    Franco Scaldaferri
    Department of Internal Medicine, Catholic University, Rome, Italy
    Cell Adh Migr 3:296-9. 2009
    ..Specific local inhibition of MAPK activity on endothelial cells and fibroblasts may provide a new mechanism to control mucosal inflammation and leukocyte recruitment into the intestine of active IBD patients...
  63. ncbi request reprint Tolerance in intestinal inflammation and cancer
    Marisa Vulcano
    Laboratory of Gastroenterology and Immunopathology, Division of Gastroenterology, Instituto Clinico Humanitas, Milan, Italy
    Curr Drug Targets 9:404-12. 2008
    ..Nevertheless, antigen uptake and presentation seems to be a crucial factor in this issue. In this review, we will discuss the key role of immune intestinal cells in the development of mucosal immunity, tolerance and disease...
  64. ncbi request reprint Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis
    Alessandro Armuzzi
    IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy and IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy
    Inflamm Bowel Dis 20:1368-74. 2014
    ..The aim of the study was to describe the long-term outcome of IFX treatment in steroid-dependent UC and investigate if predictors of sustained clinical response and colectomy could be identified...
  65. doi request reprint Comparison between 1.5 and 3.0 Tesla magnetic resonance enterography for the assessment of disease activity and complications in ileo-colonic Crohn's disease
    Gionata Fiorino
    IBD Center, Gastroenterology, IRCCS Humanitas, Via Manzoni 56, 20089, Rozzano, Milan, Italy
    Dig Dis Sci 58:3246-55. 2013
    ..Three-Tesla magnetic resonance (3T) increases signal-to-noise ratio (SNR) and reduces time of image acquisition (IAT). Whether 3T increases the accuracy of MRI in CD compared to 1.5T is unknown...
  66. ncbi request reprint Inflammation and coagulation in inflammatory bowel disease: The clot thickens
    Silvio Danese
    Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Am J Gastroenterol 102:174-86. 2007
    ..Overall, an overview is provided that the coagulation system represents an important, though previously underestimated, component of IBD pathogenesis, and may be a possible target for therapeutic intervention...
  67. doi request reprint Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study
    Gionata Fiorino
    IBD Center, Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Inflamm Bowel Dis 18:1042-7. 2012
    ..We aimed to evaluate the response rates to pneumococcal vaccination in four different treatment groups (mesalamine, azathioprine, infliximab, infliximab plus azathioprine)...
  68. pmc Risk of postoperative recurrence and postoperative management of Crohn's disease
    Antonino Spinelli
    Department and Chair of General Surgery, University of Milan, Istituto Clinico Humanitas IRCCS, Via Manzoni 5620089, Rozzano, Milan, Italy
    World J Gastroenterol 17:3213-9. 2011
    ....
  69. doi request reprint The role of JAM-A in inflammatory bowel disease: unrevealing the ties that bind
    Stefania Vetrano
    Division of Gastroenterology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Ann N Y Acad Sci 1165:308-13. 2009
    ..This review focuses on the role of JAM-A in controlling mucosal homeostasis by regulating the integrity and permeability of epithelial barrier function...
  70. ncbi request reprint Vascular involvement in inflammatory bowel disease: pathogenesis and clinical aspects
    Alfredo Papa
    Department of Internal Medicine, Division of Gastroenterology, Catholic University of Rome, Rome, Italy
    Dig Dis 26:149-55. 2008
    ....
  71. ncbi request reprint Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa
    S Danese
    Dept. of Clinical Chemistry, Gemelli Hospital, Catholic University, Rome, Italy
    Scand J Gastroenterol 36:247-50. 2001
    ..Assessment of CagA status might be useful to discriminate patients in which H. pylori eradication is advisable...
  72. ncbi request reprint Thrombopoietin serum levels in patients with inflammatory bowel disease with and without previous thromboembolic events
    Alfredo Papa
    Department of Internal Medicine, Catholic University of Rome, Italy
    Hepatogastroenterology 50:132-5. 2003
    ..However, the available data are not conclusive. The aim of this study was to assess thrombopoietin serum levels in inflammatory bowel disease patients according to platelet counts, disease activity and previous thrombotic events...
  73. ncbi request reprint Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds
    Tiziana Di Pucchio
    Istituto Superiore di Sanita, Department of Cell Biology and Neurosciences, Rome, Italy
    Expert Opin Ther Pat 20:229-50. 2010
    ..Recently, IDO has been implicated in B-cell stimulation and autoantibody production in experimental models of autoimmune diseases...
  74. ncbi request reprint Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance
    Sergio Rutella
    Department of Hematology, Laboratory of Immunology, Catholic University School of Medicine, Rome, Italy
    J Immunol 175:7085-91. 2005
    ..This review summarizes the growing body of evidence that supports a critical role for G-CSF as a novel mediator of T cell tolerance...
  75. ncbi request reprint Review article: inherited thrombophilia in inflammatory bowel disease
    Alfredo Papa
    Department of Internal Medicine, Catholic University of Rome, Rome, Italy
    Am J Gastroenterol 98:1247-51. 2003
    ..In the last few years, a great amount of literature has focused on the prevalence of such genetic mutations and their role in determining thrombosis in IBD patients. In this review, we summarize the results of these studies...
  76. ncbi request reprint Biological therapy for ulcerative colitis: what is after anti-TNF
    Gionata Fiorino
    IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy
    Curr Drug Targets 12:1433-9. 2011
    ..They include anti TNF-α agents, anti adhesion molecules, anti IL-12/23, anti IL-6R and more. We review the recent advances in biological therapy for UC treatment beyond the anti-TNFs...
  77. ncbi request reprint A novel pathogenic role for microvasculature in inflammatory bowel disease
    S Danese
    Department of Internal Medicine, Catholic University of Rome, Rome, Italy
    Eur Rev Med Pharmacol Sci 10:3-5. 2006
    ..Interestingly, endothelium has become one of the major areas of investigation in gut inflammation...
  78. ncbi request reprint The role of magnetic resonance imaging in detecting intestinal fibrosis in Crohn's disease
    Gionata Fiorino
    IBD Center, IRCCS Humanitas, Via Manzoni 56, Rozzano, Milan, Italy
    Curr Drug Targets 13:1273-9. 2012
    ..We will then briefly review the main mechanisms of fibrosis in this condition and the use of MRI in CD focusing on findings predictive of fibrosis and fibrotic evolution...
  79. doi request reprint Adalimumab in ulcerative colitis: hypes and hopes
    Gionata Fiorino
    IBD Unit, Gastroenterology, IRCCS Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Expert Opin Biol Ther 11:109-16. 2011
    ..Adalimumab is a fully human anti-TNF-α antibody that is effective and safe for the treatment of luminal and fistulising CD...
  80. doi request reprint MRI in Crohn's disease--current and future clinical applications
    Gionata Fiorino
    Division of Gastroenterology and Digestive Endoscopy, Istituto Clinico Humanitas, Via Manzoni 56, Rozzano, Milan 20089, Italy
    Nat Rev Gastroenterol Hepatol 9:23-31. 2012
    ..This damage-driven therapeutic approach could potentially change the course of Crohn's disease...
  81. doi request reprint Regulation of leukocyte recruitment by the long pentraxin PTX3
    Livija Deban
    Laboratory for Immunology and Inflammation, Instituto di Ricovero e Cura a Carattere Scientifico Istituto Clinico Humanitas, Rozzano, Italy
    Nat Immunol 11:328-34. 2010
    ....
  82. ncbi request reprint Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer
    Silvio Danese
    Department of Internal Medicine, Università Cattolica del S Cyore, Rome, Italy
    Gastroenterology 126:369-71. 2004
  83. ncbi request reprint Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment
    Erika Angelucci
    Division of Gastroenterology, Policlinico Umberto I, Universita Sapienza, Rome, Italy
    Curr Med Chem 15:2527-35. 2008
    ..e. MMX-budesonide), have also been developed to allow uniform release along the length of the colon. This paper reviews the mechanism-of-action, safety and efficacy of budesonide in the treatment of inflammatory bowel disease...
  84. pmc Balanced propofol sedation administered by nonanesthesiologists: The first Italian experience
    Alessandro Repici
    Department of Gastroenterology, IRCCS Istituto Clinico Humanitas, Via Manzoni 56 20089 Rozzano, Milan, Italy
    World J Gastroenterol 17:3818-23. 2011
    ..To assess the efficacy and safety of a balanced approach using midazolam in combination with propofol, administered by non-anesthesiologists, in a large series of diagnostic colonoscopies...
  85. pmc Intestinal microbiota in inflammatory bowel disease: friend of foe?
    Francesca Fava
    Inflammatory Bowel Disease Unit, Istituto Clinico Humanitas, Via Manzoni 113, 20089 Rozzano, Milano, Italy
    World J Gastroenterol 17:557-66. 2011
    ..Studies looking at gut microbial composition, epithelial integrity and mucosal immune markers in genotyped IBD populations are therefore warranted to shed light on this obscure pathogenesis...
  86. ncbi request reprint Review article: potential therapeutic applications and mechanisms of action of heparin in inflammatory bowel disease
    A Papa
    Department of Internal Medicine, Catholic University of Rome, Italy
    Aliment Pharmacol Ther 14:1403-9. 2000
    ..In conclusion, unfractioned heparin may represent a safe therapeutic option for severe, steroid-resistant ulcerative colitis, although randomized, controlled trials are needed to confirm these data...
  87. ncbi request reprint Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa
    A Papa
    Institute of Internal Medicine, Giovanni XXIII Cancer Research Center and Institute of General Pathology, Institute of Pathology, Catholic University of Rome, Italy
    Scand J Gastroenterol 37:409-13. 2002
    ..pylori status and cytotoxic associated gene product A (CagA); 2) to determine the relationship between ROS generation and amount of 8-OHdG...
  88. pmc Laparoscopic surgery for recurrent Crohn's disease
    Antonino Spinelli
    Dipartimento e Cattedra di Chirurgia Generale, Istituto Clinico Humanitas IRCCS, Universita degli Studi di Milano, Rozzano, Milano, Italy
    Gastroenterol Res Pract 2012:381017. 2012
    ..The reported results indicate that laparoscopy may be safely applied even in selected recurrent CD cases in hands of IBD surgeons with broad laparoscopic experience...
  89. ncbi request reprint Metal stents for malignant colorectal obstruction
    Alessandro Repici
    Department of Gastroenterology, Digestive Endoscopy Unit, IRCCS Istituto Clinico Humanitas, Via Manzoni 56, I 20089 Rozzano, Milan, Italy
    Minim Invasive Ther Allied Technol 15:331-8. 2006
    ....
  90. doi request reprint Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease
    G Fiorino
    GI Unit, Dipartimento di Scienze Cliniche, Policlinico Umberto I, Rome, Italy
    Aliment Pharmacol Ther 29:921-7. 2009
    ..An emerging challenge is the increasing incidence of anti TNF-alpha induced psoriasis. A total of 120 cases have been currently reported, of whom 18 patients were treated with biological agents for IBD...
  91. ncbi request reprint Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis
    S Vetrano
    Laboratory of Immunology and Inflammation and Division of Gastroenterology, Istituto Clinico Humanitas, Viale Manzoni, Rozzano, Milan, Italy
    Int J Immunopathol Pharmacol 21:401-7. 2008
    ..MIP-1, MIP-2 and RANTES concentrations in colonic organ culture were significantly lower in colifagina-treated mice than in the placebo group. The use of colifagina is effective in amelioration of murine colitis...
  92. ncbi request reprint Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease
    A Papa
    Department of Internal Medicine, Gastroenterology Unit, Catholic University of Rome, A Gemelli University Hospital, Largo A Gemelli 8, 00168 Rome, Italy
    Dig Liver Dis 36:528-32. 2004
    ..Intercellular adhesion molecule 1 gene lies on chromosome 19p13, implicated in determining susceptibility to inflammatory bowel disease. Recently, the polymorphism K469E of intercellular adhesion molecule 1 gene has been identified...
  93. ncbi request reprint Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria
    V Ojetti
    Department of Internal Medicine, Catholic University, Rome, Italy
    Int Arch Allergy Immunol 125:66-72. 2001
    ..CONCLUSIONS: Although H. pylori infection affects gastric juice ECP and eosinophil infiltration of ICU patients, the role of the bacterium in the pathogenesis of this skin disorder still remains uncertain...
  94. pmc The CD40/CD40L costimulatory pathway in inflammatory bowel disease
    S Danese
    Department of Internal Medicine, Catholic University, Rome, Italy
    Gut 53:1035-43. 2004
  95. ncbi request reprint High prevalence of celiac disease in patients with lactose intolerance
    Veronica Ojetti
    Internal Medicine, Catholic University, Rome, Italy
    Digestion 71:106-10. 2005
    ..We evaluated the prevalence of celiac disease in patients with a positive H2-lactose breath test compared to a control group...
  96. pmc Etiopathogenesis of inflammatory bowel diseases
    Silvio Danese
    Division of Gastroenterology, Istituto Clinico Humanitas IRCCS in Gastroenterology, Milan, Italy
    World J Gastroenterol 12:4807-12. 2006
    ..Gut inflammation is mediated by cells of the innate as well as adaptive immune systems, with the additional contribution of non-immune cells, such as epithelial, mesenchymal and endothelial cells, and platelets...
  97. ncbi request reprint Efficacy and tolerability of antibiotics in patients undergoing H. pylori eradication
    S Danese
    Internal Medicine Department, Gemelli Hospital, Catholic University, Rome, Italy
    Hepatogastroenterology 48:465-7. 2001
    ..Quadruple therapy, which appear highly efficacious as a second line therapy, is associated with a significantly higher incidence of side effects when compared to first-line treatment...
  98. ncbi request reprint Early atherosclerosis in patients with inflammatory bowel disease
    A Papa
    Department of Internal Medicine, Gastroenterology Unit, Catholic University of Rome, Italy
    Eur Rev Med Pharmacol Sci 10:7-11. 2006
    ....
  99. ncbi request reprint Antibodies to Saccharomyces cerevisiae: are they useful in clinical practice?
    M Candelli
    Department of Internal Medicine, Catholic University of Sacred Heart, Rome, Italy
    Hepatogastroenterology 50:718-20. 2003
    ..The aim of this study was to assess the sensitivity and specificity of antibodies to Saccharomyces cerevisiae for Crohn's disease in an Italian population and to evaluate their clinical role...
  100. ncbi request reprint Increased carotid intima-media thickness in patients with inflammatory bowel disease
    A Papa
    Department of Internal Medicine, Gastroenterology Unit, Catholic University of Rome, Rome, Italy
    Aliment Pharmacol Ther 22:839-46. 2005
    ..Patients with inflammatory bowel disease have an increased risk of thrombotic complications; moreover, mesenteric microvascular thrombosis has been hypothesized as a contributing factor in the pathogenesis of inflammatory bowel disease...
  101. ncbi request reprint Prevalence of and risk factors for Helicobacter pylori infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study
    A Gasbarrini
    Department of Medical Pathology, Gemelli Hospital, Catholic University, Rome, Italy
    Eur J Gastroenterol Hepatol 13:185-9. 2001
    ..To evaluate the prevalence of and the risk factors for Helicobacter pylori in a population of medical and non-medical workers at a teaching hospital in Rome, Italy...